Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
- B1123 RosuvastatinSummary: Competitive inhibitor of HMG-CoA reductase
- B1240 (+)-KetoconazoleSummary: Potent inhibitor of cytochrome P450c17
- B1124 PitavastatinSummary: HMG-CoA reductase inhibitor
- B1125 PravastatinSummary: HMG-CoA reductase inhibitor against sterol synthesis
- B1165 Pimobendan hydrochlorideSummary: Selective inhibitor of PDE3
- B1947 GemfibrozilSummary: PPARα activator
- N1705 IcariinSummary: PDE5 inhibitor
- B1593 IrsogladineSummary: PDE4 inhibitor
- B3422 U-731221 CitationTarget: PC-PLCSummary: inhibitor of phospholipase C, phospholipase A2, and 5-LO (5-lipoxygenase)
- B3439 UdenafilTarget: Phosphodiesterases (PDEs)Summary: PDE5 inhibitor